Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on treatments for obesity and metabolic diseases [2]. Group 3: Allegations - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Group 4: Stock Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. on behalf of investors who acquired Skye securities during the specified Class Period, alleging misleading information regarding the company's lead candidate, nimacimab [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit claims that throughout the Class Period, the defendants misled investors about the prospects of nimacimab [2]. - Investors are given a deadline of January 16, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Stock Performance Impact - On October 6, 2025, Skye published topline findings from its Phase 2a CBeyond trial of nimacimab, which failed to meet its primary weight-loss endpoint compared to placebo. Following this announcement, Skye's stock price dropped by $2.85 per share, approximately 60%, closing at $1.90 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [3]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab [4]. - Specific claims include that nimacimab was less effective than represented, and its clinical and commercial prospects were overstated [4]. - The lawsuit asserts that these misleading statements resulted in investor damages when the true information became public [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its drug nimacimab during the class period from November 4, 2024, to October 3, 2025 [7]. Allegation Details - The lawsuit claims that Skye's management overstated the effectiveness of nimacimab, leading to inflated expectations regarding its clinical, regulatory, and commercial prospects [7]. - Specific allegations include that nimacimab was less effective than represented, and that the public statements made by the defendants were materially false and misleading [7]. Stock Price Impact - Following the announcement of disappointing clinical trial results on October 6, 2025, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share [7]. Next Steps for Investors - Investors who purchased Skye securities during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 16, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation [5]. - The firm has a nationwide practice and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience is a San Diego-based biotech company focused on therapies for obesity and metabolic diseases [2]. - On October 6, 2025, Skye announced that its Phase 2a CBeyond study of nimacimab did not meet its primary weight-loss endpoint compared to placebo, resulting in a 60% drop in share price, from $4.75 to $1.90 [4].

Core Insights - Skye Bioscience, Inc. is focused on advancing nimacimab, a peripherally restricted CB1-inhibiting antibody, to address obesity and metabolic health disorders in 2026 [1][2] Clinical Development - In 2025, Skye generated Phase 2a clinical data, enhancing understanding of nimacimab's exposure-response dynamics and laying the groundwork for higher dose testing and a subsequent Phase 2 trial [2] - The 2026 goals include delivering additional clinical readouts from the CBeyond extension study, selecting higher doses of nimacimab, and launching a Phase 2b study to evaluate multiple doses as a monotherapy and in combination with incretin therapy [2][8] - The CBeyond Phase 2a 26-week extension data update and interim results are expected in Q1 2026, with topline results to 52 weeks anticipated in Q3 2026 [5][12] Preclinical and Clinical Insights - Preclinical research has validated the broad potential utility of nimacimab, showing significant weight loss in DIO mouse models both as a monotherapy and in combination with other treatments [4][6] - The combination of nimacimab with semaglutide demonstrated clinically meaningful additional weight loss without plateauing at 26 weeks, along with favorable safety and tolerability profiles [6][11] Manufacturing and Scalability - Skye is advancing manufacturing scale-up and CMC execution to produce nimacimab for planned follow-on studies, focusing on higher dosing and optimal drug administration [11] - Collaborations have been initiated to develop a higher concentration formulation of nimacimab and to create a subcutaneous formulation that may facilitate larger injection volumes [11] Strategic Focus - Skye aims to unlock new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors, with nimacimab positioned as a potential first-in-class therapy [9][11]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the Class Period from November 4, 2024, to October 3, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by January 16, 2026 [2]. - The lawsuit claims that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Rosen Law Firm is investigating allegations that Skye Bioscience, Inc. misled investors regarding its business operations during the specified period [1] Group 1: Company Overview - Skye Bioscience, Inc. is identified as a clinical stage biopharmaceutical company [1] Group 2: Legal Investigation - The investigation pertains to securities purchased between November 4, 2024, and October 3, 2025 [1] - Investors are reminded to submit a form, email attorney Phillip Kim, or call for more information regarding the allegations [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025 [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4]. - The claims suggest that when the true details about nimacimab were revealed, investors suffered damages due to the misleading information provided by the defendants [4].

NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra ...